NCT05937828 OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
| NCT ID | NCT05937828 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Immune Thrombocytopenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,500 participants |
| Start Date | 2010-09-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,500 participants in total. It began in 2010-09-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
From 2004, OBS'CEREVANCE is a national real-world prospective clinical cohort of patients with auto-immune cytopenia of pediatric-onset : Immune thrombocytopenia (ITP), Autoimmune Hemolytic anemia (AIHA), or Evans syndrome (all bi or tri cytopenias). Thanks to the collaboration of the 30 French pediatric hematologic centers, this cohort supports all of the Rare Disease Centre CEREVANCE (Centre de Référence National des Cytopénies Auto-Immunes de l'Enfant) missions for care, education and research. Specifically, this original unbiased database allows to describe the long-term health of adult patients, to identify the heterogenous genetic underlying pathophysiologic contexts, and to study the benefit-risk balance of treatments, including the growing development of targeted therapies.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of ITP, AIHA, Evans Syndrome * Onset before the age of 18 Exclusion Criteria: * Opposition of legal representative or to data collection
Contact & Investigator
Nathalie ALADJIDI, MD
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT05937828 clinical trial?
This trial is open to participants of all sexes, up to 17 Years, studying Immune Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05937828 currently recruiting?
Yes, NCT05937828 is actively recruiting participants. Contact the research team at nathalie.aladjidi@chu-bordeaux.fr for enrollment information.
Where is the NCT05937828 trial being conducted?
This trial is being conducted at Amiens, France, Angers, France, Besançon, France, Bordeaux, France and 5 additional locations.
Who is sponsoring the NCT05937828 clinical trial?
NCT05937828 is sponsored by University Hospital, Bordeaux. The principal investigator is Nathalie ALADJIDI, MD at University Hospital, Bordeaux. The trial plans to enroll 3,500 participants.